Channel therapeutics corp CHRO.US Overview Analysis
CHRO AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
CHRO Current Performance
2.75%
Channel therapeutics corp
1.31%
Avg of Sector
0.58%
S&P500
Top 10 High Relevance to CHRO
- AXSM Axsome therapeutics incValue 2Trend 3Swing Trading 5Whale Interest 3Dividend 1See more
CHRO Profile
Channel Therapeutics Corporation is engaged in developing innovative, non-addictive, drugs to treat chronic neuropathic and acute and chronic eye pain. The Company is focused on the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. It is initially targeting orphan chronic pain indications, specifically small fiber neuropathy and erythromelalgia, and acute and chronic eye pain. The Company's patented, selective, and potent (nM) inhibitor of human NaV1.7 has demonstrated additional efficacy in several models of pain: acute, chronic, inflammatory, visceral, post-surgical, and chemotherapy-induced.